Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects

Meyer Halberstam, Neil Cohen, Pavel Shlimovich, Luciano Rossetti, Harry Shamoon

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

We compared the effects of oral vanadyl sulfate (100 mg/day) in moderately obese NIDDM and nondiabetic subjects. Three-hour euglycemic-hyperinsulinemic (insulin infusion 30 mU · m-2 · min-1) clamps were performed after 2 weeks of placebo and 3 weeks of vanadyl sulfate treatment in six nondiabetic control subjects (age 37 ± 3 years; BMI 29.5 ± 2.4 kg/m2) and seven NIDDM subjects (age 53 ± 2 years; BMI 28.7 ± 1.8 kg/m2). Glucose turnover ([3- 3H]glucose), glycolysis from plasma glucose, glycogen synthesis, and whole- body carbohydrate and lipid oxidation were evaluated. Decreases in fasting plasma glucose (by ~1.7 mmol/l) and HbA(1c) (both P < 0.05) were observed in NIDDM subjects during treatment; plasma glucose was unchanged in control subjects. In the latter, the glucose infusion rate (GIR) required to maintain euglycemia (40.1 ± 5.7 and 38.1 ± 4.8 μmol · kg fat-free mass [FFM]-1 · min-1) and glucose disposal (R(d)) (41.7 ± 5.7 and 38.9 ± 4.7 μmol · kg FFM-1 · min-1) were similar during placebo and vanadyl sulfate administration, respectively. Hepatic glucose output (HGO) was completely suppressed in both studies. In contrast, in NIDDM subjects, vanadyl sulfate increased GIR ~82% (17.3 ± 4.7 to 30.9 ± 2.7 μmol · kg FFM-1 · min- 1, P < 0.05); this improvement in insulin sensitivity was due to both augmented stimulation of R(d) (26.0 ± 4.0 vs. 33.6 ± 2.22 μmol · kg FFM- 1 · min-1, P < 0.05) and enhanced suppression of HGO (7.7 ± 3.1 vs. 1.3 ± 0.9 μmol · kg FFM-1 · min-1, P < 0.05). Increased insulin- stimulated glycogen synthesis accounted for >80% of the increased R(d) with vanadyl sulfate (P < 0.005), but plasma glucose flux via glycolysis was unchanged. In NIDDM subjects, vanadyl sulfate was also associated with greater suppression of plasma free fatty acids (FFAs) (P < 0.01) and lipid oxidation (P < 0.05) during clamps. The reduction in HGO and increase in R(d) were both highly correlated with the decline in plasma FFA concentrations during the clamp period (P < 0.001). In conclusion, small oral doses of vanadyl sulfate do not alter insulin sensitivity in nondiabetic subjects, but it does improve both hepatic and skeletal muscle insulin sensitivity in NIDDM subjects in part by enhancing insulin's inhibitory effect on lipolysis. These data suggest that vanadyl sulfate may improve a defect in insulin signaling specific to NIDDM.

Original languageEnglish (US)
Pages (from-to)659-666
Number of pages8
JournalDiabetes
Volume45
Issue number5
StatePublished - May 1996

Fingerprint

Type 2 Diabetes Mellitus
Insulin Resistance
Glucose
Glycolysis
Nonesterified Fatty Acids
Insulin
Lipids
Lipolysis
Glycogen
vanadyl sulfate
Fasting
Skeletal Muscle
Placebos
Carbohydrates
Liver

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Halberstam, M., Cohen, N., Shlimovich, P., Rossetti, L., & Shamoon, H. (1996). Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes, 45(5), 659-666.

Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. / Halberstam, Meyer; Cohen, Neil; Shlimovich, Pavel; Rossetti, Luciano; Shamoon, Harry.

In: Diabetes, Vol. 45, No. 5, 05.1996, p. 659-666.

Research output: Contribution to journalArticle

Halberstam, M, Cohen, N, Shlimovich, P, Rossetti, L & Shamoon, H 1996, 'Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects', Diabetes, vol. 45, no. 5, pp. 659-666.
Halberstam, Meyer ; Cohen, Neil ; Shlimovich, Pavel ; Rossetti, Luciano ; Shamoon, Harry. / Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. In: Diabetes. 1996 ; Vol. 45, No. 5. pp. 659-666.
@article{b2e3cc4b484b420fbb9cb491703570a3,
title = "Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects",
abstract = "We compared the effects of oral vanadyl sulfate (100 mg/day) in moderately obese NIDDM and nondiabetic subjects. Three-hour euglycemic-hyperinsulinemic (insulin infusion 30 mU · m-2 · min-1) clamps were performed after 2 weeks of placebo and 3 weeks of vanadyl sulfate treatment in six nondiabetic control subjects (age 37 ± 3 years; BMI 29.5 ± 2.4 kg/m2) and seven NIDDM subjects (age 53 ± 2 years; BMI 28.7 ± 1.8 kg/m2). Glucose turnover ([3- 3H]glucose), glycolysis from plasma glucose, glycogen synthesis, and whole- body carbohydrate and lipid oxidation were evaluated. Decreases in fasting plasma glucose (by ~1.7 mmol/l) and HbA(1c) (both P < 0.05) were observed in NIDDM subjects during treatment; plasma glucose was unchanged in control subjects. In the latter, the glucose infusion rate (GIR) required to maintain euglycemia (40.1 ± 5.7 and 38.1 ± 4.8 μmol · kg fat-free mass [FFM]-1 · min-1) and glucose disposal (R(d)) (41.7 ± 5.7 and 38.9 ± 4.7 μmol · kg FFM-1 · min-1) were similar during placebo and vanadyl sulfate administration, respectively. Hepatic glucose output (HGO) was completely suppressed in both studies. In contrast, in NIDDM subjects, vanadyl sulfate increased GIR ~82{\%} (17.3 ± 4.7 to 30.9 ± 2.7 μmol · kg FFM-1 · min- 1, P < 0.05); this improvement in insulin sensitivity was due to both augmented stimulation of R(d) (26.0 ± 4.0 vs. 33.6 ± 2.22 μmol · kg FFM- 1 · min-1, P < 0.05) and enhanced suppression of HGO (7.7 ± 3.1 vs. 1.3 ± 0.9 μmol · kg FFM-1 · min-1, P < 0.05). Increased insulin- stimulated glycogen synthesis accounted for >80{\%} of the increased R(d) with vanadyl sulfate (P < 0.005), but plasma glucose flux via glycolysis was unchanged. In NIDDM subjects, vanadyl sulfate was also associated with greater suppression of plasma free fatty acids (FFAs) (P < 0.01) and lipid oxidation (P < 0.05) during clamps. The reduction in HGO and increase in R(d) were both highly correlated with the decline in plasma FFA concentrations during the clamp period (P < 0.001). In conclusion, small oral doses of vanadyl sulfate do not alter insulin sensitivity in nondiabetic subjects, but it does improve both hepatic and skeletal muscle insulin sensitivity in NIDDM subjects in part by enhancing insulin's inhibitory effect on lipolysis. These data suggest that vanadyl sulfate may improve a defect in insulin signaling specific to NIDDM.",
author = "Meyer Halberstam and Neil Cohen and Pavel Shlimovich and Luciano Rossetti and Harry Shamoon",
year = "1996",
month = "5",
language = "English (US)",
volume = "45",
pages = "659--666",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects

AU - Halberstam, Meyer

AU - Cohen, Neil

AU - Shlimovich, Pavel

AU - Rossetti, Luciano

AU - Shamoon, Harry

PY - 1996/5

Y1 - 1996/5

N2 - We compared the effects of oral vanadyl sulfate (100 mg/day) in moderately obese NIDDM and nondiabetic subjects. Three-hour euglycemic-hyperinsulinemic (insulin infusion 30 mU · m-2 · min-1) clamps were performed after 2 weeks of placebo and 3 weeks of vanadyl sulfate treatment in six nondiabetic control subjects (age 37 ± 3 years; BMI 29.5 ± 2.4 kg/m2) and seven NIDDM subjects (age 53 ± 2 years; BMI 28.7 ± 1.8 kg/m2). Glucose turnover ([3- 3H]glucose), glycolysis from plasma glucose, glycogen synthesis, and whole- body carbohydrate and lipid oxidation were evaluated. Decreases in fasting plasma glucose (by ~1.7 mmol/l) and HbA(1c) (both P < 0.05) were observed in NIDDM subjects during treatment; plasma glucose was unchanged in control subjects. In the latter, the glucose infusion rate (GIR) required to maintain euglycemia (40.1 ± 5.7 and 38.1 ± 4.8 μmol · kg fat-free mass [FFM]-1 · min-1) and glucose disposal (R(d)) (41.7 ± 5.7 and 38.9 ± 4.7 μmol · kg FFM-1 · min-1) were similar during placebo and vanadyl sulfate administration, respectively. Hepatic glucose output (HGO) was completely suppressed in both studies. In contrast, in NIDDM subjects, vanadyl sulfate increased GIR ~82% (17.3 ± 4.7 to 30.9 ± 2.7 μmol · kg FFM-1 · min- 1, P < 0.05); this improvement in insulin sensitivity was due to both augmented stimulation of R(d) (26.0 ± 4.0 vs. 33.6 ± 2.22 μmol · kg FFM- 1 · min-1, P < 0.05) and enhanced suppression of HGO (7.7 ± 3.1 vs. 1.3 ± 0.9 μmol · kg FFM-1 · min-1, P < 0.05). Increased insulin- stimulated glycogen synthesis accounted for >80% of the increased R(d) with vanadyl sulfate (P < 0.005), but plasma glucose flux via glycolysis was unchanged. In NIDDM subjects, vanadyl sulfate was also associated with greater suppression of plasma free fatty acids (FFAs) (P < 0.01) and lipid oxidation (P < 0.05) during clamps. The reduction in HGO and increase in R(d) were both highly correlated with the decline in plasma FFA concentrations during the clamp period (P < 0.001). In conclusion, small oral doses of vanadyl sulfate do not alter insulin sensitivity in nondiabetic subjects, but it does improve both hepatic and skeletal muscle insulin sensitivity in NIDDM subjects in part by enhancing insulin's inhibitory effect on lipolysis. These data suggest that vanadyl sulfate may improve a defect in insulin signaling specific to NIDDM.

AB - We compared the effects of oral vanadyl sulfate (100 mg/day) in moderately obese NIDDM and nondiabetic subjects. Three-hour euglycemic-hyperinsulinemic (insulin infusion 30 mU · m-2 · min-1) clamps were performed after 2 weeks of placebo and 3 weeks of vanadyl sulfate treatment in six nondiabetic control subjects (age 37 ± 3 years; BMI 29.5 ± 2.4 kg/m2) and seven NIDDM subjects (age 53 ± 2 years; BMI 28.7 ± 1.8 kg/m2). Glucose turnover ([3- 3H]glucose), glycolysis from plasma glucose, glycogen synthesis, and whole- body carbohydrate and lipid oxidation were evaluated. Decreases in fasting plasma glucose (by ~1.7 mmol/l) and HbA(1c) (both P < 0.05) were observed in NIDDM subjects during treatment; plasma glucose was unchanged in control subjects. In the latter, the glucose infusion rate (GIR) required to maintain euglycemia (40.1 ± 5.7 and 38.1 ± 4.8 μmol · kg fat-free mass [FFM]-1 · min-1) and glucose disposal (R(d)) (41.7 ± 5.7 and 38.9 ± 4.7 μmol · kg FFM-1 · min-1) were similar during placebo and vanadyl sulfate administration, respectively. Hepatic glucose output (HGO) was completely suppressed in both studies. In contrast, in NIDDM subjects, vanadyl sulfate increased GIR ~82% (17.3 ± 4.7 to 30.9 ± 2.7 μmol · kg FFM-1 · min- 1, P < 0.05); this improvement in insulin sensitivity was due to both augmented stimulation of R(d) (26.0 ± 4.0 vs. 33.6 ± 2.22 μmol · kg FFM- 1 · min-1, P < 0.05) and enhanced suppression of HGO (7.7 ± 3.1 vs. 1.3 ± 0.9 μmol · kg FFM-1 · min-1, P < 0.05). Increased insulin- stimulated glycogen synthesis accounted for >80% of the increased R(d) with vanadyl sulfate (P < 0.005), but plasma glucose flux via glycolysis was unchanged. In NIDDM subjects, vanadyl sulfate was also associated with greater suppression of plasma free fatty acids (FFAs) (P < 0.01) and lipid oxidation (P < 0.05) during clamps. The reduction in HGO and increase in R(d) were both highly correlated with the decline in plasma FFA concentrations during the clamp period (P < 0.001). In conclusion, small oral doses of vanadyl sulfate do not alter insulin sensitivity in nondiabetic subjects, but it does improve both hepatic and skeletal muscle insulin sensitivity in NIDDM subjects in part by enhancing insulin's inhibitory effect on lipolysis. These data suggest that vanadyl sulfate may improve a defect in insulin signaling specific to NIDDM.

UR - http://www.scopus.com/inward/record.url?scp=0029985240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029985240&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 659

EP - 666

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 5

ER -